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Single-stranded DNA binding protein 2 (SSBP2) is ubiquitously expressed, with several
studies reporting it to be a tumor suppressor. We investigated SSBP2 expression and its
clinicopathological significance in gastric cancer. SSBP2 expression was examined by
immunohistochemistry in 539 gastric cancer sections. The cases were divided into three
subtypes, namely, Epstein–Barr virus-associated (EBV), microsatellite unstable, and others
(microsatellite stable and EBV negative), based on the molecular classification of The Can-
cer Genome Atlas (TCGA). Cases were also divided into two subgroups according to the
amplification status of human epidermal growth factor receptor 2 (HER2). Most cases
showed SSBP2 positivity, and only 24 (4.5%) cases displayed negative nuclear expression.
Loss of nuclear expression correlated significantly with high pT category (P = 0.001), nodal
metastasis (P = 0.002), and stage of progression (P = 0.005), with no correlation between
molecular characteristics and SSBP2 expression. All HER2 amplification cases displayed
positive SSBP2 expression. Negative SSBP2 cases showed significantly shorter recur-
rence-free survival (RFS) compared to positive SSBP2 cases (P = 0.008). Loss of nuclear
expression of SSBP2 was significantly associated with shorter RFS in the microsatellite sta-
ble and EBV negative groups (P = 0.002), as well as the HER2 negative group (P = 0.007).
However, there were no statistically significant differences in multivariate analyses. Loss of
nuclear expression of SSBP2 was a poor prognostic factor, associated with stage of pro-
gression and recurrence, and showed no significant difference in molecular characteristics,
including TCGA subtype and HER2 status.
Introduction
The GLOBOCAN database (September 2018 edition) of The International Agency for
Research on Cancer (IARC) indicates that gastric cancer is the sixth most common cancer and
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the third most common cause of mortality worldwide, with the highest incidence being in
Eastern Asia, including Korea [1, 2].
Gastric cancer is a common malignant tumor of the digestive system and a heterogeneous
disease with diverse histopathological characteristics. Therefore, several histological classifica-
tions such as the Lauren classification (intestinal, diffuse, mixed and indeterminate type) and
WHO classification (tubular, papillary, mucinous, and poorly cohesive carcinoma) are avail-
able [3, 4]. The Cancer Genome Atlas (TCGA) research network recently divided the molecu-
lar classification of gastric cancer into four subgroups: Epstein–Barr virus (EBV),
microsatellite instability (MSI), genomic stability (GS), and chromosomal instability (CIN)
associated tumors [5]. Surgical resection and adjuvant therapy are the main treatment modali-
ties. In advanced gastric cancers (AGC), the probability of metastasis or peritoneal seeding dis-
semination is still high with poor overall prognosis [6]. Many studies have therefore been
conducted on molecular targeted therapies in addition to conventional chemotherapy [7].
Single-stranded DNA binding protein 2 (SSBP2) is known to be a candidate tumor suppres-
sor in patients with myeloid leukemia located at chromosome 5q14 [8–10]. SSBP2 binds to the
transcriptional cofactor Lim-domain-binding protein 1 (LDB1) and enhances LDB1 stability
to regulate gene expression [11]. The role of SSBP2 has also been studied in several solid
tumors including hepatocellular carcinoma, gallbladder cancer, esophageal squamous cell car-
cinoma, and prostate cancer. Most studies, except for a recent report on hepatocellular carci-
noma, have reported SSBP2 to have tumor suppressive action [12–15]. Maldonado et al. [16]
found that decreased SSBP2 expression was associated with an increased risk of recurrence in
advanced prostate cancer. However, no studies are available regarding the expression of SSBP2
in gastric cancer.
Therefore, we tried to identify the expression of SSBP2 through immunohistochemistry in
gastric cancer and analyzed the association of expression and prognosis. The differences in
SSBP2 expression, according to molecular subtypes and HER2 status, were also investigated.
Materials and methods
Patients
We retrospectively collected 561 gastric cancer patients who underwent surgical resection at
Hanyang University Hospital, between February 2005 and August 2010. Among them, 505
patients underwent gastrectomy, 54 patients had received endoscopic submucosal dissections
(ESD), and two patients had received wedge resections. Two patients with AGC were excluded
from the study due to neoadjuvant chemotherapy. We also excluded patients who had distant
metastasis at the time of AGC diagnosis (seven cases), or who did not have an adequate surgi-
cal margin (one case). Twelve cases were excluded as they did not have enough tumor tissue
for the study (AGC cases: two, early gastric cancer cases undergoing gastrectomy: three, early
gastric cancer cases undergoing ESD: seven). Consequently, 539 patients were included in this
study. Medical records were reviewed to determine the following clinical characteristics: age,
sex, follow-up interval, and survival, and recurrence status.
Ethics statement
Data anonymization was performed after enrolling 561 patients and completing a case report
form. We deleted all personally identifiable information and constructed a database that can
distinguish each case only by case number. The study protocol conformed to the ethical guide-
lines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Board
of the Hanyang University Hospital (HYUH 2019-04-032-001), and the requirement for
informed consent was waived.
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Pathological evaluation
We reviewed all hematoxylin and eosin (H&E) slides used at the time of diagnosis. Pathologic
features included tumor location (center of tumor), tumor size, gross type, histological type of
WHO classification, Lauren classification, lymphatic or vascular invasion, perineural invasion,
and stage of tumor-node-metastasis (TMN). Cardia, fundus, and body were considered for the
proximal stomach, while angle, antrum, and pylorus were regarded for the distal stomach.
Early gastric cancer (EGC) was classified as type I to type III. Type II tumors were further
divided into IIa, IIb, and IIc. When two or more gross types coexisted, they were classified as
mixed type. The gross appearance of AGC was classified as type 1 to type 4, according to Borr-
mann’s classification [3]. It was regarded as a lymphatic invasion when the tumor invaded the
small vessel. The invasion of the large vessel with the muscle layer was regarded as a venous
invasion. The histological type was based on 2010 WHO classifications, with TMN stage based
on the American Joint Committee on Cancer (AJCC) 8th edition. Pathological evaluations
were performed by two pathologists, independently (SSB and SJS).
Tissue microarray construction
Tissue microarray (TMA) was prepared using a tissue microarray system (Tissue Microarray
Set, Labro, Seoul, Korea). Formalin-fixed paraffin-embedded (FFPE) tissue samples taken from
resected primary tumors at the time of initial diagnosis were collected exclusively. The represen-
tative tumor area was selected by light microscopy of H&E-stained sections, and 3.0 mm core
tissue microarray (TMA) blocks were constructed with two representative cores for each case.
Immunohistochemistry and interpretation
The immunohistochemical staining for SSBP2 was performed in 4 μm sections obtained from
TMA blocks. Deparaffinization was performed by immersing the sections in xylene solution.
Rehydration was performed using a graded series of ethanol. Heat-induced epitope retrieval
was performed by autoclave heating at 100 ˚C for 20 min in sodium citrate buffer (pH 6.0).
After cooling, blocking of endogenous peroxidase was performed using a peroxidase-blocking
solution (S2023, Dako, Glostrup, Denmark) for 15 min. The sections were incubated in a
humidified chamber with a diluted (1:200) primary antibody overnight at 4˚C. The recombi-
nant anti-SSBP2 antibody (ab177944, Abcam, Cambridge, UK) was used as a primary anti-
body. The sections were subsequently incubated with a Labeled Polymer (K5007, EnVisionTM
Detection System, Dako) for 30 min at room temperature. We used 3,3’-diaminobenzidine tet-
rahydrochloride (DAB) chromogen (K5007, EnVisionTM Detection System, Dako) to detect
the antigen-antibody complex. Finally, hematoxylin (Mayer’s) counterstain and mounting
coverslips were performed on the slides.
SSBP2 expression was evaluated by two pathologists (SB and SS) who were blinded to clinical
data, according to tumor cell nuclear staining using a light microscope. Tumor cells showing posi-
tive nuclear staining was defined as positive SSBP2 expression, regardless of intensity and propor-
tion. Tumor cells showing a complete lack of nuclear staining were defined as negative (Fig 1).
Microsatellite instability status
Immunohistochemical staining of MLH1 (G168-728, Cell Marque, CA, USA), PMS2 (MRQ-
28, Cell Marque, CA, USA), MSH2 (G219-1129, Cell Marque, CA, USA), and MSH6 (PU29,
Leica Biosystems, Nussloch, Germany) was performed to confirm the expression of mismatch
repair proteins. Staining was performed in representative blocks (whole sections) of primary
tumors. The cases showing loss of expression in all tumor cells were defined as negative. The
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nuclei of normal epithelium and inflammatory cells were regarded as internal controls. The
tumors positive for all four immunohistochemical stains were classified as microsatellite stable
(MSS). Those that gave negative results for one or more of the four immunohistochemical
stains were classified as MSI.
Epstein-Barr virus status
We detected EBV through the EBV-encoded RNA in situ hybridization (EBER-ISH) tech-
nique. The INFORM EBER Probe (Roche, Basel, Switzerland) was used to perform automated
staining on TMA slides, according to the manufacturer’s instructions. Positive staining was
defined by diffuse staining of tumor cells.
HER2 status
HER2 DNA amplification was assessed with the silver DNA in situ hybridization (SISH) tech-
nique on TMA slides. The INFORM HER2 Dual ISH DNA probe cocktail (Roche, Basel, Switzer-
land), with HER2 probe and chromosome 17 (CEP17) probe, was used for staining. Automated
staining was performed according to the protocol of Ventana Benchmark XT staining systems.
The number of black (HER2) and red (CEP17) signals were counted. We considered that a HER2
/ CEP17 ratio of� 2.0 was amplified, and a HER2 / CEP17 ratio of<2.0 was not amplified.
Statistical analysis
The correlation between SSBP2 expression and clinicopathologic features was calculated with
Pearson’s chi-square (χ2) or Fisher’s exact tests. Overall survival (OS) was defined as the time
from diagnosis with gastric cancer to death. Recurrence-free survival (RFS) was defined as the
time from surgical treatment to the first recurrence, either clinically or pathologically. Survival
curves were constructed using the Kaplan–Meier method and the influence of variables was
analyzed using a log-rank test. The univariate and multivariate Cox regression analyses were
used to determine significant prognostic variables. In all analyses, two-sided P values<0.05
were regarded as statistically significant. Data analysis was performed using SPSS software ver-
sion 25.0 (IBM, Armonk, USA).
Results
Clinicopathologic and molecular characteristics
The clinicopathologic characteristics of 539 patients are summarized in S1 Table. The median
follow-up period was 118 months (range, 1–166 months). Among 539 patients, 302 (56.0%)
Fig 1. Immunohistochemical staining of single-stranded DNA binding protein 2 (SSBP2) in gastric adenocarcinoma
(a: negative, b, positive; x200; scale bar: 100 μm).
https://doi.org/10.1371/journal.pone.0236896.g001
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patients received curative surgical resection only, and 237 (44.0%) patients received curative
surgical resection plus adjuvant chemotherapy. Of 237 patients, 129 (23.9%) patients received
fluoropyrimidine-based chemotherapy, 6 (1.1%) patients received platinum-based chemother-
apy, and 102 (18.9%) patients received fluoropyrimidine plus platinum chemotherapy.
According to the TCGA molecular subtypes of gastric adenocarcinoma, the 539 gastric cancer
cases were classified into EBV (35 cases, 6.5%), MSI (44 cases, 8.2%), and ‘others’ (460 cases,
85.3%) subgroups. EBER-ISH positive cases were considered to be of EBV subtype, whereas,
cases were classified as MSI when one or more of the four mismatch repair proteins displayed
negative results. GS and CIN subtypes were not distinguished in this study but rather classified
as EBV negative or MSS (S2 Table). HER2 status was classified separately from TCGA sub-
types. HER2 amplification was seen in 26 cases (4.8%) and none of these were included in the
EBV or MSI subtypes.
SSBP2 expression and clinicopathological features
The correlation between SSBP2 expression and clinicopathological features in patients with
gastric adenocarcinoma is shown in Table 1. Overall, 515 cases (95.5%) were positive for
nuclear staining, and 24 cases (4.5%) displayed complete negative staining. Loss of nuclear
SSBP2 expression was significantly correlated with high pT category (P = 0.001), nodal metas-
tasis (P = 0.002), and stage of progression (P = 0.005). No statistically significant correlations
were found between SSBP2 expression and other clinicopathological features.
SSBP2 expression and molecular characteristics
There was no correlation between molecular characteristics and SSBP2 expression. One EBV
positive case and three MSI cases displayed a loss of nuclear SSBP2 expression. Of the 460 EBV
negative and MSS cases (CIN or GS subtype), 20 cases (4.3%) showed a loss of SSBP2 expres-
sion. All 26 HER2 amplification cases showed positive SSBP2 expression (Table 2).
Prognostic significance of SSBP2 expression
In the 539 patients with gastric carcinomas, loss of SSBP2 expression was associated with
shorter RFS and OS (P = 0.008 and P = 0.072, respectively; Fig 2). Univariate analyses revealed
that other factors might be associated with a shorter RFS, including undifferentiated histologi-
cal type (P = 0.001), diffuse and mixed type of Lauren classification (P< 0.001), high pT cate-
gory (P< 0.001), nodal metastasis (P< 0.001), high AJCC stage (P< 0.001), lymphovascular
invasion (P< 0.001), and perineural invasion (P< 0.001). In the multivariate analysis, a high
AJCC stage (P< 0.001) was significantly related to poor prognostic factors, while a loss of
SSBP2 expression was not statistically significant (Table 3).
In the MSS and EBV negative gastric cancer group, Kaplan-Meier survival curves also
showed that a loss of nuclear SSBP2 expression was associated with shorter RFS and OS
(P = 0.002 and P = 0.087, respectively; Fig 3A and 3B). However, the loss of SSBP2 expression
lost statistical significance in the multivariate analysis (S3 Table). Of the cases with MSI, there
was no recurrence during the follow-up period and SSBP2 expression had no prognostic
implication for OS in MSI groups. In the HER2 negative group, patients with loss of SSBP2
expression also displayed shorter RFS and OS (P = 0.007 and P = 0.058, respectively; Fig 3C
and 3D). Once again, the loss of SSBP2 expression lost statistical significance during the multi-
variate analyses (S4 Table).
We also divided into subgroups receiving fluoropyrimidine-based chemotherapy and
groups receiving platinum-based chemotherapy and fluoropyrimidine plus platinum chemo-
therapy and analyzed the difference in the clinical outcome of each group according to the loss
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of SSBP2 expression. SSBP2 expression had no prognostic implication for RFS and OS in
fluoropyrimidine-based chemotherapy group (P = 0.818 and P = 0.790, respectively). How-
ever, loss of SSBP2 expression was significantly associated shorter OS (P = 0.024) in platinum-
based chemotherapy (with or without fluoropyrimidine) group, and the differences were not
statistically significant in RFS (P = 0.114).
Discussion
This study showed that loss of SSBP2 expression is: significantly associated with stage progres-
sion and poor prognosis (1), associated with poor prognosis in MSS/EBV negative and HER2
negative subtypes (2), and not correlated with molecular characteristics (3).
Table 1. Correlation between single-stranded DNA binding protein 2 expression and clinicopathological features in patients with gastric adenocarcinoma
(n = 539).
Variables Negative (n = 24) Positive (n = 515) P-value
Age 0.314
< 65 years 17 (5.2%) 312 (94.8%)
� 65 years 7 (3.3%) 203 (96.7%)
Sex 0.581
Male 18 (4.8%) 359 (95.2%)
Female 6 (3.7%) 156 (96.3%)
Location 0.324
Proximal 11 (5.6%) 185 (94.4%)
Distal 13 (3.8%) 330 (96.2%)
Histologic type� 0.607
Differentiated 12 (5.0%) 230 (95.0%)
Undifferentiated and others 12 (4.0%) 285 (96.0%)
Lauren 0.378
Intestinal 14 (5.2%) 253 (94.8%)
Diffuse and mixed 10 (3.7%) 262 (96.3%)
pT category 0.001
pT1 and pT2 8 (2.3%) 336 (97.7%)
pT3 and pT4 16 (8.2%) 179 (91.8%)
Nodal status 0.002
Negative 7 (2.2%) 315 (97.8%)
Positive 17 (7.8%) 200 (92.2%)
Stage† 0.005
I 7 (2.3%) 300 (97.7%)
II and III 17 (7.3%) 215 (92.7%)
Lymphovascular invasion 0.079
Absent 8 (2.9%) 266 (97.1%)
Present 16 (6.0%) 249 (94.0%)
Perineural invasion 0.073
Absent 11 (3.2%) 329 (96.8%)
Present 13 (6.5%) 186 (93.5%)
�Differentiated: well-differentiated, moderately differentiated adenocarcinoma; undifferentiated: poorly differentiated, signet ring cell carcinoma; others: papillary,
mucinous, adenosquamous, hepatoid, gastric carcinoma with lymphoid stroma, adenocarcinoma with choriocarcinomatous differentiation
†AJCC 8th edition.
https://doi.org/10.1371/journal.pone.0236896.t001
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The effect of SSBP2 on the carcinogenesis and progression of malignant tumors is not yet
clear. One of the known functions of SSBP2 is to bind LDB1 and regulate LDB1 activity. LDB1
regulates the differentiation of luminal cells in the gastrointestinal tract [17] and cardiomyo-
cytes [18] and is also involved in cancer progression [11, 19]. Several studies on the promoter
methylation of SSBP2 in tumors have shown that it is one of the genes downregulated by meth-
ylation [13–15, 20, 21]. Promoter hypermethylation of SSBP2 was observed in several solid
tumors, including gall bladder cancer, esophageal squamous cell carcinoma, prostate cancer,
ovarian cancer, and hepatocellular carcinoma [13–15, 20, 22]. SSBP2 functioned as a tumor
suppressor in gall bladder cancer, esophageal squamous cell carcinoma, and prostate cancer.
Jun-Wei et al. [15] reported that SSBP2 promoter hypermethylation was found in 61.4% of
prostate cancer cases, whereas none of the benign prostatic hyperplasia cases showed hyper-
methylation. They also showed that SSBP2 expression, by immunohistochemistry, was signifi-
cantly downregulated in most primary prostate cancer cases compared to normal prostatic
tissues.
The prognostic impact of SSBP2 expression in gastric cancer, determined by immunohis-
tochemistry, has not been reported. In this study, we investigated the expression of SSBP2 and
its prognostic role in gastric adenocarcinoma. Focal or diffuse patterns of nuclear SSBP2
expression were observed in most cases (95.5%), with only 4.5% of all cases showing complete
Table 2. Correlation between single-stranded DNA binding protein 2 expression and molecular characteristics in patients with gastric adenocarcinoma (n = 539).
Variables Negative (n = 24) Positive (n = 515) P-value
EBV status
Negative 23 (4.6%) 481 (95.4%) 1.000
Positive 1 (2.9%) 34 (97.1%)
MSI status
MSS 21 (4.2%) 474 (95.8%) 0.434
MSI 3 (6.8%) 41 (93.2%)
HER2 status
No amplification 24 (4.7%) 489 (95.3%) 0.622
Amplification 0 (0.0%) 26 (100%)
Abbreviations: EBV, Epstein–Barr virus; MSI, Microsatellite instability; MSS, microsatellite stable.
https://doi.org/10.1371/journal.pone.0236896.t002
Fig 2. Kaplan-Meier analysis of SSBP2 in gastric adenocarcinoma. (a) Recurrence-free survival (RFS) was
significantly worse in patients with loss of SSBP2 expression compared to those with positive expression, and (b)
overall survival (OS) was worse in patients with loss of SSBP2 expression compared to those with positive expression.
https://doi.org/10.1371/journal.pone.0236896.g002
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negativity. Complete loss of nuclear expression of SSBP2 was correlated with a high pT cate-
gory and lymph node metastasis, suggesting an association with progression of the gastric ade-
nocarcinoma. Loss of expression of SSBP2 was also associated with shorter RFS and OS.
We attempted to divide 539 adenocarcinoma cases according to the TCGA molecular clas-
sification. The immunohistochemistry for mismatch repair proteins and EBER-ISH was per-
formed to identify the MSI and EBV subtype, while GS and CIN subtypes were not
distinguished. The EBV subtype was 6.5%, and MSI subtype was 8.2% in our study. Results
from the TCGA data indicated that the proportion of EBV and MSI groups was relatively
Table 3. The univariate and multivariate Cox regression analyses for recurrence-free survival (RFS) and overall survival (OS) in patients with gastric adenocarci-
noma (n = 539).
Recurrence-free survival (RFS)
Variables Univariate analysis Multivariate analysis
HR 95% CI P-values HR 95% CI P-values
SSBP2 expression (positive vs. negative) 2.438 1.231–4.828 0.008 1.646 0.828–3.273 0.155
Age group (<65 vs.�65) 1.019 0.687–1511 0.926
Sex (female vs. male) 1.029 0.677–1.566 0.892
Location (distal vs. proximal) 1.127 0.761–1668 0.551
Histologic type
�
(differentiated vs. undifferentiated and others) 2.040 1.341–3.102 0.001
Lauren classification (intestinal vs. diffuse and mixed) 2.304 1.526–3.479 <0.001 1.452 0.955–2.208 0.081
pT category (T1-2 vs. T3-4) 11.175 6.720–18.583 <0.001
Nodal status (negative vs. positive) 10.841 6.361–18.476 <0.001
Stage† (I vs. II, III) 14.857 7.950–27.768 <0.001 5.642 2.388–13.330 <0.001
Lymphovascular invasion (absent vs. present) 10.981 5.877–20.518 <0.001 2.177 0.948–4.998 0.066
Perineural invasion (absent vs. present) 8.307 5.187–13.303 <0.001 1.576 0.868–2.863 0.135
EBV status (negative vs. positive) 1.001 0.465–2.155 0.998
MSI status (MSI vs. MSS) 23.217 1.234–436.886 0.036
HER2 amplification (negative vs. positive) 1.247 0.547–2.843 0.599
Overall survival (OS)
Variables Univariate analysis Multivariate analysis
HR 95% CI P-values HR 95% CI P-values
SSBP2 expression (positive vs. negative) 1.698 0.946–3.047 0.073 1.382 0.767–2.489 0.282
Age group (<65 vs.�65) 1.999 1.504–2.658 <0.001 2.080 1.564–2.767 <0.001
Sex (female vs. male) 1.155 0.840–1.588 0.376
Location (distal vs. proximal) 1.091 0.814–1.461 0.562
Histologic type� (differentiated vs. undifferentiated and others) 0.963 0.725–1.280 0.797
Lauren classification (intestinal vs. diffuse and mixed) 1.095 0.825–1.455 0.530
pT category (T1-2 vs. T3-4) 3.616 2.705–4.832 <0.001
Nodal status (negative vs. positive) 3.335 2.488–4.471 <0.001
Stage† (I vs. II, III) 3.586 2.655–4.843 <0.001 2.371 1.445–3.890 0.001
Lymphovascular invasion (absent vs. present) 2.805 2.071–3.800 <0.001 1.058 0.662–1.691 0.813
Perineural invasion (absent vs. present) 3.243 2.430–4.328 <0.001 1.658 1.060–2.593 0.027
EBV status (negative vs. positive) 1.032 0.588–1.812 0.913
MSI status (MSI vs. MSS) 1.306 0.743–2.293 0.354
HER2 amplification (negative vs. positive) 1.640 0.934–2.881 0.085
�Differentiated: well-differentiated, moderately differentiated adenocarcinoma; undifferentiated: poorly differentiated, signet ring cell carcinoma; others: papillary,
mucinous, adenosquamous, hepatoid, gastric carcinoma with lymphoid stroma, adenocarcinoma with choriocarcinomatous differentiation
†AJCC 8th edition.
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval.
https://doi.org/10.1371/journal.pone.0236896.t003
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small in our cohort (9% and 22% in TCGA, respectively) [5]. According to recent reports of
subtype prognosis in the TCGA cohort, EBV subtypes have the best prognosis [23], although
our study showed no significant difference. The number of positive HER2 positive cases in our
study was smaller (4.8%). as compared to other studies (from 6.0 to 29.5%) [24]. HER2 positive
cases had shorter OS than negative cases, but this was not statistically significant. Although all
HER2 positive cases showed SSBP2 expression, there was no significant association between
SSBP2 expression with EBV, MSI, and HER amplification status.
There were several limitations to our study. This was a retrospective study conducted on
539 cases. Cases of EBV, MSI, and HER2 amplification subtype were too few to give significant
results. Therefore, larger-scale studies are needed to confirm the association between molecu-
lar characteristics and SSBP2 expression and the prognostic significance of SSBP2 for each
molecular characteristic. Also, we evaluated the expression of SSBP2 by immunohistochemis-
try only, and could not explain the underlying mechanism. The association of molecular alter-
ations according to the molecular subtypes of gastric cancer, such as MLH1 hypermethylation,
and promoter methylation of SSBP2 is not yet known. Further studies are needed to confirm
the association between molecular subtypes and SSBP2, and these studies will also help these
studies will help to understand the role of SSBP2 and its effect on carcinogenesis and cancer
progression in gastric cancer.
In conclusion, we investigated the pattern of SSBP2 expression through immunohis-
tochemistry, as well as its clinicopathological significance in patients with gastric adenocarci-
noma. Loss of SSBP2 expression was a poor prognostic factor associated with stage
Fig 3. Kaplan-Meier analysis of SSBP2 in microsatellite stable (MSS) and EBV negative group (a and b), and in HER2
negative group (c and d). Recurrence-free survival (RFS) was significantly worse in patients with loss of SSBP2
expression compared to those with positive expression in MSS and EBV negative (a) and HER2 negative (c) groups.
Overall survival (OS) was worse in patients with loss of SSBP2 expression compared to those with SSBP2 positive
expression in MSS and EBV negative (b) and HER2 negative (d) groups.
https://doi.org/10.1371/journal.pone.0236896.g003
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progression and recurrence. We also reported that SSBP2 expression did not show significant
differences according to molecular characteristics, including TCGA molecular subtype and
HER2 status.
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